Insta
AstraZeneca
India is set to conduct a deeper review of post-vaccination side effects of the COVID-19 vaccine developed by pharmaceutical major AstraZeneca and the University of Oxford next week, reports Economic Times.
The development comes at a time when several nations like Denmark, Norway and Iceland have suspended the use of the said vaccine over isolated reports of recipients developing blood clots after the vaccine administration.
It should be noted though the World Health Organisation (WHO) has stated that there was no reason for nations to stop the use of the said vaccine.
NK Arora, a member of India's national task force on COVID-19 has said, "We are looking at all the adverse events, particularly serious adverse events like deaths and hospitalisation. We will come back if we find anything of concern."
Arora has also stated that there is "no immediate issue of concern as the number of adverse events (in India) is very, very low." He added, "We are relooking to see if there was any issue of blood clotting."
It should be noted that India has already administered at least 28 million doses under its nationwide inoculation campaign, most of which have been AstraZeneca's vaccine manufactured by Pune-based Serum Institute of India.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.
Latest